
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-02-01-2010
- Volume 22
- Issue 2
Implications and Opportunities of Applying QbD Principles to Analytical Measurement
The authors present two concepts to improve robustness and facilitate continuous improvement in analytical methods.
The authors present two concepts to improve robustness and facilitate continuous improvement in analytical methods.
The merits of applying quality by design (QbD) to pharmaceutical products and processes is a topic of significant mutual interest to both pharmaceutical manufacturers and regulatory agencies. The pharmaceutical industry is currently embracing QbD concepts to help improve the robustness of manufacturing processes and to facilitate continuous improvement strategies to shape and enhance product quality and manufacturing productivity. As such, both industry and regulators recognize the benefits of adopting a QbD approach to drug-product development and manufacture, with key concepts described in International Conference on Harmonization (ICH) guidelines Q8(R1) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System.
Articles in this issue
almost 16 years ago
EU pricing dilemmasalmost 16 years ago
Is change good for you?almost 16 years ago
Newsalmost 16 years ago
Multivariate data analysis easily retrieves insight from a wealth of dataalmost 16 years ago
Rise of the robotsalmost 16 years ago
Your predictions for 2010almost 16 years ago
Commercialising cellular therapies fasteralmost 16 years ago
Cushioning pharma's fall from the patent precipicealmost 16 years ago
Biopharmaceuticals: saving the future of our industryalmost 16 years ago
Achieving site-specific PEGylationNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





